Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation. .
【中文题目：驱动基因阳性非小细胞肺癌免疫治疗进展】 【中文摘要：肺癌是目前世界上致死率最高的恶性肿瘤，其中约80%为非小细胞肺癌（non-small cell lung cancer, NSCLC）。大部分NSCLC患者伴有“驱动基因突变”，针对突变基因的靶向治疗可取得较好的疗效，但仍有部分患者在治疗后会出现进展或复发，预后较差。已有的研究表明，免疫检查点抑制剂可改善晚期NSCLC的预后，延长患者生存期。但对于具有不同免疫微环境和分子特性的NSCLC患者，免疫治疗的效果差异较大。其中免疫治疗在驱动基因阳性的NSCLC患者中的地位存在比较大的争议。本文对驱动基因阳性NSCLC的免疫特点及免疫治疗在驱动基因阳性患者中的应用前景和挑战进行综述。 】 【中文关键词：肺肿瘤；驱动基因阳性；免疫治疗】.
Keywords: Driver gene; Immune therapy; Lung neoplasms.